Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, G6 and G7, which may have health risks for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 less reliable than previous versions, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability and accuracy, were allegedly overstated, and the company downplayed the severity of the issues related to the G7 devices [3]. Group 2: Legal and Financial Implications - The allegations suggest that DexCom is facing increased regulatory scrutiny and potential enforcement actions, which could lead to significant legal, reputational, and financial harm [3]. - The public statements made by DexCom during the class period are claimed to be materially false and misleading, impacting investor trust and stock performance [3]. Group 3: Class Action Participation - Shareholders who purchased shares of DXCM between January 8, 2024, and September 17, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 26, 2025 [4]. - Once registered, shareholders will receive updates on the case through a portfolio monitoring software, with no cost or obligation to participate [4].

Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence through various research services [1][2] Group 1: Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the short term [3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7] Group 2: Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] - Stocks with lower ranks, even with good Style Scores, may still face downward price pressure due to negative earnings outlooks [11] Group 3: Company Spotlight - DexCom, Inc. - DexCom, Inc. is a medical device company specializing in continuous glucose monitoring systems for diabetes management [12] - Currently rated 3 (Hold) by Zacks, DexCom has a VGM Score of A and a Growth Style Score of A, indicating strong growth potential [12][13] - The company is projected to achieve year-over-year earnings growth of 26.2% for the current fiscal year, with upward revisions in earnings estimates from analysts [13]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the DexCom securities is from July 26, 2024, to September 17, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The deadline to move the Court to serve as lead plaintiff is December 29, 2025 [2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability [4] - It is claimed that these changes presented a material health risk to users relying on the devices for accurate glucose readings [4] - The defendants allegedly downplayed the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who suffered losses exceeding $100,000 during the specified class period to seek legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - The defendants are accused of making misleading statements regarding the reliability and functionality of the G6 and G7 devices, which led to increased regulatory scrutiny and potential financial harm to the company [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - To participate in the class action, investors can visit the provided link or contact the firm directly for more information [3][6].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - Defendants allegedly made unauthorized design changes to the G6 and G7 systems that compromised their reliability and safety [2]. - The enhancements claimed for the G7 device were reportedly overstated, leading to potential health risks for users relying on these devices for accurate glucose readings [2]. - DexCom is accused of downplaying the severity of issues related to the G7 devices, which could result in increased regulatory scrutiny and significant legal and financial repercussions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the enhancements to the G7 device were overstated, and the true scope of issues related to the G7 devices was downplayed by the defendants [5]. - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [5].

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The complaint asserts that the enhancements to the G7 and its reliability, accuracy, and functionality were overstated by the defendants [2] - Defendants allegedly downplayed the severity of the issues and health risks associated with the altered G7 devices [2] - The lawsuit indicates that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - As a result, the public statements made by the defendants were claimed to be materially false and misleading [2] Group 2: Next Steps for Affected Investors - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information via the provided link or contact the firm directly for further details [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including a notable recovery of over $438 million for investors in 2019 [4]. - Investors are advised that until a class is certified, they are not represented unless they retain counsel, and they have the option to remain absent from the class [7].

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DexCom, Inc. (NASDAQ:DXCM) and Wildermuth Fund (NASDAQ:WEFCX, NASDAQ:WESFX. NASDAQ:WEIFX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. DexCom, Inc. (NASDAQ:DXCM) Class Period: ...

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability [2]. - The design changes reportedly posed a material health risk to users who relied on these devices for accurate glucose readings [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, while downplaying the severity of issues related to adulterated devices [2]. - The company faces increased regulatory scrutiny and potential legal, reputational, and financial harm due to these allegations [2]. Group 2: Legal Process for Investors - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and selects counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].